HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced the topline results of the study of HTD1801 in primary sclerosing cholangitis (PSC) will be presented at the International Liver Congress 2021, 23-26 June

HighTide Therapeutics (“HighTide”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for non-viral chronic liver diseases, gastrointestinal diseases,

HighTide Therapeutics (“HighTide”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for non-viral chronic liver diseases, gastrointestinal diseases, and metabolic disorders, announced that its

HighTide Therapeutics (“HighTide”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for non-viral chronic liver diseases, gastrointestinal diseases

HighTide Therapeutics today announced that the Company will present at the fifth annual NASH-TAG Conference. The hybrid (in-person/virtual) conference, focused on therapeutic agents for non-alcoholic steatohepatitis (NASH) and liver fibrosis

HighTide Therapeutics today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright Global Life Sciences Conference March 9-10, 2021.